Cargando…
Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years
BACKGROUND: This prospective, open-label trial was conducted to fulfil a post-approval commitment made to the competent authorities to extend the indication of the strong opioid analgesic tapentadol hydrochloride oral solution (OS) to the pediatric population. PATIENTS AND METHODS: The trial assesse...
Autores principales: | Jończyk, Renata, Beuter, Christoph, Bulawa, Beata, Buller, Stefan, Eibl, Christoph, Elling, Christian, Gautrois, Michael, Rengelshausen, Jens, Schmidt, Carsten, Thömmes, Guido, Khalil, Feras |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531608/ https://www.ncbi.nlm.nih.gov/pubmed/36203787 http://dx.doi.org/10.2147/JPR.S364902 |
Ejemplares similares
-
Outcomes of the Pediatric Development Plan of Tapentadol
por: Eerdekens, Mariëlle, et al.
Publicado: (2021) -
Tapentadol for the Treatment of Moderate-to-Severe Acute Pain in Children Under the Age of Two Years
por: Eissa, Ayman, et al.
Publicado: (2021) -
Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years – a randomized, double-blind, placebo-controlled trial
por: Beuter, Christoph, et al.
Publicado: (2019) -
Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old
por: Khalil, Feras, et al.
Publicado: (2020) -
Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients
por: Muse, Derek, et al.
Publicado: (2019)